Psychotropic Drug Use in Pregnancy

  • Lee S. Cohen
  • Jerrold F. Rosenbaum
  • Vicki L. Heller


The pregnant psychiatric patient on or requiring psychotropic medication presents an unusual clinical dilemma, often placing the physician between a teratologic rock and a clinical hard place.1 Although ethical considerations have precluded adequately controlled studies with pregnant woman, the rate of psychotropic use in pregnancy2,3 together with the prevalence of certain psychiatric conditions in women during pregnancy4 and in women of childbearing potential5 in general underscore the need for treatment guidelines to help clinicians manage pregnant patients with psychiatric disorders.


Anxiety Disorder Psychotropic Drug Panic Disorder Nephrogenic Diabetes Insipidus Bipolar Mood Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cohen L. S., Heller V. L., Rosenbaum J. F.: Treatment guidelines for psychotropic drug use in pregnancy. Psychosomatics 30:25–33, 1989.PubMedCrossRefGoogle Scholar
  2. 2.
    Doering J. C., Stewart R. B.: The extent and character of drug consumption during pregnancy. JAMA 239:843–846, 1978.PubMedCrossRefGoogle Scholar
  3. 3.
    Kasilo O., Romero M., Bonati M., et al: Information on drug use in pregnancy from the Viewpoint Regional Drug Information Center. Eur J Clin Pharmacol 35:447–453, 1988.PubMedCrossRefGoogle Scholar
  4. 4..
    O’Hara M. W., Zekoski E. M., Phillips L. H., et al: A controlled prospective study of postpartum mood disorders: Comparison of childbearing and nonchildbearing women. J Abnorm Psychol (in press).Google Scholar
  5. 5.
    Frank E., Kupfer D. J., Jacob M., et al: Pregnancy related affective episodes among women with recurrent depression. Am J Psychiatry 144:288–293, 1987.PubMedGoogle Scholar
  6. 6.
    Calabrese J. R., Gulledge A. D.: Psychotropics during pregnancy and lactation: A review. Psychosomatics 26:413–426, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    Robinson G. E., Stewart D. E., Flak E.: The rational use of psychotropic drugs in pregnancy and postpartum. Can J Psychiatry 31:183–190, 1986.PubMedGoogle Scholar
  8. 8.
    Slone D., Siskind V., Heinonen O. P., et al: Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality age, birth weight and intelligence quotient score. Am J Obstet Gynecol 128:486–488, 1977.PubMedGoogle Scholar
  9. 9.
    Rumeau-Rouguette C., Goujard J., Huel G.: Possible teratogenic effect of phenothiazines in human beings. Teratology 15:57–64, 1977.CrossRefGoogle Scholar
  10. 10.
    Milkovich L., Van den Berg B. J.: An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 125:244–248, 1976.PubMedGoogle Scholar
  11. 11.
    Edlund M. J., Craig T. J.: Antipsychotic drug use and birth defects: An epidemiologic reassessment. Compr Psychiatry 25:32–37, 1984.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuenssberg E. V., Knox J. D.: Imipramine in pregnancy. Br Med J 2:292, 1972.PubMedCrossRefGoogle Scholar
  13. 13.
    Idanpaan-Heikkila J., Saxen L.: Possible teratogenicity of imipramine-chloropyramine. Lancet 2:282–284, 1973.PubMedCrossRefGoogle Scholar
  14. 14.
    Czeizel A., Lendvay A.: In-utero exposure to benzodiazepines (letter). Lancet 1:628, 1987.Google Scholar
  15. 15.
    Rosenberg L., Mitchell A., Parsells J., et al: Lack of relation of oral cleft to diazepam use during pregnancy. N Engl J Med 309:1282–1285, 1983.PubMedCrossRefGoogle Scholar
  16. 16.
    Shiono B. H., Mills J. L.: Oral clefts and diazepam use during pregnancy (letter). N Engl J Med 311:919–920, 1984.PubMedCrossRefGoogle Scholar
  17. 17.
    Langman J.: Human development-normal and abnormals, in Langman J. (ed.): Medical Embryology (ed. 5). Baltimore, Williams & Wilkins, 1985, p 123.Google Scholar
  18. 18.
    Dicke J. M.: Teratology: Principles and practice. Med Clin North Am 73:567–581, 1989.PubMedGoogle Scholar
  19. 19.
    Coyle I. R.: Changes in developing behavior following prenatal administration of imipramine. Pharmacol Biochem Behav 3:799–807, 1975.PubMedCrossRefGoogle Scholar
  20. 20.
    Robertson R. T., Majka J. A., Peter C. P., et al: Effects of prenatal exposure to chlorpromazine on postnatal development and behavior of rats. Toxicol Appl Pharmacol 53:541–549, 1980.PubMedCrossRefGoogle Scholar
  21. 21.
    Kellogg C., Ison J., Miller R.: Prenatal diazepam exposure: Effects on auditory temporal resolution in rats. Psychopharmacology 79:332–337, 1983.PubMedCrossRefGoogle Scholar
  22. 22.
    Miller G. C., Friedhoff A. G.: Prenatal neurotransmitter programming of postnatal receptor function. Prog Brain Res 2:509–522, 1987.Google Scholar
  23. 23.
    Webster P. A. C.: Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 2:318–319, 1973.PubMedCrossRefGoogle Scholar
  24. 24.
    Shearer W. T., Schreiner R. L., Marshall R. E.: Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 81:570–572, 1972.PubMedCrossRefGoogle Scholar
  25. 25.
    Cree J. E., Meyer J., Hailey D. M.: Diazepam in labour: Its metabolism and effect on the clinical condition and thermogenesis of the newborn. Br Med J 4:251–255, 1973.PubMedCrossRefGoogle Scholar
  26. 26.
    Hill R. M., Desmond M. M., Kay J. L.: Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr 69:589–595, 1966.PubMedCrossRefGoogle Scholar
  27. 27.
    Tamer A., McKey R., Arias D., et al: Phenothiazine-induced extrapyramidal dysfunction in the neonate. J Pediatr 7:479–480, 1969.Google Scholar
  28. 28.
    Levy W., Wisniewski K.: Chlorpromazine causing extrapyramidal dysfunction in newborn infants of psychotic mothers. NY State J Med 74:684–685, 1974.Google Scholar
  29. 29.
    Gelenberg A. J.: Pregnancy, psychotropic drugs, and psychiatric disorders. Psychosomatics 27:216–217, 1986.PubMedCrossRefGoogle Scholar
  30. 30.
    Gelenberg A. J.: Psychotropic drugs during pregnancy and the perinatal period. Biol Ther Psychiatry 2:41–42, 1979.Google Scholar
  31. 31.
    Nahas C., Goujard J.: Phenothiazines, benzodiazepines and the fetus, in Scarpelli E. M., Cosmi E. V. (eds): Reviews in Perinatal Medicine. New York, Raven Press, 1978, pp 243–280.Google Scholar
  32. 32.
    Rivera-Calimlin L.: The significance of drugs in breastmilk: Pharmacokinetic considerations. Clin Perinatol 14:51–70, 1987.Google Scholar
  33. 33.
    Anderson P. O., McGuire G. G.: Neonatal alprazolam withdrawal-possible effects of breast feeding. Drug Intell Clin Pharm 23:614, 1989.Google Scholar
  34. 34.
    Gelenberg A. J.: Antidepressants in milk. Biol Ther Psychiatry 10:1, 1987.Google Scholar
  35. 35.
    Charney D., Heninger G.: Abnormal regulation of noradrenergic function in panic disorder. Arch Gen Psychiatry 43:1042–1054, 1986.PubMedCrossRefGoogle Scholar
  36. 36.
    Siever L., Uhde T.: New studies and perspectives on the noradrenergic receptor system in depression: Effects of the alpha two adrenergic agonist clonidine. Biol Psychiatry 19:131–156, 1984.PubMedGoogle Scholar
  37. 37.
    Cohen L. S., Rosenbaum J. F., Heller V. L.: Panic attack-associated placental abruption: A case report. J Clin Psychiatry 50:266–267, 1989.PubMedGoogle Scholar
  38. 38.
    Avant K.: Anxiety as a potential factor affecting maternal attachment. J Obstet Gynecol Neonatal Nurs 10:416–419, 1981.CrossRefGoogle Scholar
  39. 39.
    Brazelton T. B.: Mother infant reciprocity, in Klaus M. H., Leger T., Trause M. A. (eds): Maternal Attachment and Mothering Disorders: A Roundtable. North Brunswick, NJ, Johnson & Johnson, 1975.Google Scholar
  40. 40.
    Zahn-Waxler C., Cummings E. M., Ianoff R. J., et al: Young offspring of depressed patients: A population of risk for affective problems and childhood depression, in Cichetti D., C Schneider-Rosen (eds): Childhood Depression. San Francisco, Jossey-Bass, 1984.Google Scholar
  41. 41.
    Cogill S. R., Caplan H. L., Alexandra H., et al: Impact of maternal depression of cognitive development of young children. Br Med J 292:1165–1167, 1986.CrossRefGoogle Scholar
  42. 42.
    Sapolsky R.: Stress glucocorticoids and the rate of brain aging. Presented at Annual Meeting of the American College of Neuropsychopharmacology, December, 1988, Nashville, TN.Google Scholar
  43. 43.
    Protheroe C.: Puerperal psychoses: A long term study 1927–1961. Br J Psychiatry 115:9–30, 1961.CrossRefGoogle Scholar
  44. 44.
    Kopelman A. E., McCullar F. W., Heggeness, L.: Limb malformations following maternal use of haloperidol. JAMA 231:62–64, 1975.CrossRefGoogle Scholar
  45. 45.
    Scokel P. W., Jones W. D.: Infant jaundice after phenothiazine drugs for labour: An enigma. Obstet Gynecol 20:124–127, 1962.PubMedCrossRefGoogle Scholar
  46. 46.
    Falterman L. G., Richardson D. J.: Small left colon syndrome associated with maternal ingestion of psychotropics. J Pediatr 97:300–310, 1980.Google Scholar
  47. 47.
    Spear L. P., Shalaby I. A., Brick J.: Chronic administration of haloperidol during development: Behavioral and psychopharmacological effects. Psychopharmacology 70:47–58, 1980.PubMedCrossRefGoogle Scholar
  48. 48.
    Desmond M. M., Rudolph A. J., Hill R. M., et al: Behavioral alterations in infants born to mothers on psychoactive medication during pregnancy, in Farrell G. (ed): Congenital Mental Retardation. Austin, University of Texas, 1967.Google Scholar
  49. 49.
    Platt J. E., Friedhoff A. J., Broman S. H., et al: Effects of prenatal exposure to neuroleptic drugs on childrens growth. Neuropsychopharmacology 1:205–212, 1988.PubMedCrossRefGoogle Scholar
  50. 50.
    Kris E. B.: Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res 31:690–695, 1965.Google Scholar
  51. 51.
    Zajicek E.: Psychiatric problems during pregnancy, in Wolkind S., Zajicek E. (eds): Pregnancy: A Psychological and Social Study. London, Academic Press, 1981, pp 57–73.Google Scholar
  52. 52.
    O’Hara M. W., Neunaber D. J., Zekoski E. M.: Prospective study of postpartum depression: Prevalence, course, and predictive factors. J Abnorm Psychol 93:158–171, 1984.PubMedCrossRefGoogle Scholar
  53. 53.
    O’Hara M. W.: Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 43:573, 1986.Google Scholar
  54. 54.
    O’Hara M. W.: Postpartum blues, depression, and psychosis: A review. J Psychosom Obstet Gynecol 7:205–227, 1987.CrossRefGoogle Scholar
  55. 55.
    Targum S. D., Gershon E. S.: Pregnancy, genetic counselling and the major psychiatric disorders, in genetic diseases, in Schulman J., Simpson J. (eds): Pregnancy-Maternal Effects and Fetal Outcome. New York, Academic Press, 1981.Google Scholar
  56. 56.
    Akiskal H. S., Walker P., Puzantian V. R., et al: Bipolar outcome in the course of depressive illness: Phenomenologic, familiar, and pharmacologic predictors. J Affect Disord 5:115–128, 1983.PubMedCrossRefGoogle Scholar
  57. 57.
    McBride W. G.: Limb deformities associated with iminodibenzyl hydrochloride (letter). Med J Aust 1:492, 1972.PubMedGoogle Scholar
  58. 58.
    Crombie D., Pinsent R. J., Felming D.: Imipramine and pregnancy. Br Med J 1:745, 1972.PubMedCrossRefGoogle Scholar
  59. 59.
    Coyle I. R., Singer G.: The interaction of post-weaning housing conditions and prenatal drug effects of behavior. Psychopharmacology 41:237–244, 1975.CrossRefGoogle Scholar
  60. 60.
    Giller E., Bialos D., Riddle M., et al: Monoamine oxidase inhibitor responsive depression. Psychiatry Res 6:41–48, 1982.PubMedCrossRefGoogle Scholar
  61. 61.
    Liebowitz M. R., Quitkin F., Stewart J., et al: Phenelzine vs. imipramine in atypical depression. Arch Gen Psychiatry 41:669–677, 1984.PubMedCrossRefGoogle Scholar
  62. 62.
    Poulson E., Robson J. M.: Effect of phenelzine and some related compounds in pregnancy. J Endocrinol 30:205–215, 1964.PubMedCrossRefGoogle Scholar
  63. 63.
    Quitkin F. M.: The importance of dosage in prescribing antidepressants. Br J Psychiatry 147:593–597, 1985.PubMedCrossRefGoogle Scholar
  64. 64.
    Schou, M. Concerning the start of the Scandinavian Register of Lithium Babies. Acta Psychiatr Scand 207(suppl.):96–97, 1969.Google Scholar
  65. 65.
    Ackerman D., Jefferson J., Griest J., et al: The lithium index: An innovative approach to consultation by computer. Am J Psychiatry 141:415–417, 1984.PubMedGoogle Scholar
  66. 66.
    Weinstein M. R., Goldfield M. D.: Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 132:529–531, 1975.PubMedGoogle Scholar
  67. 67.
    Kirklin J. W., Barratt-Boyes B. G.: Ebstein’s malformation, in Kirklin J. W., Barratt-Boyes B. G. (eds): Cardiac Surgery. New York, John Wiley & Sons, 1986, pp 889–907.Google Scholar
  68. 68.
    Elia J., Katz I. R., Simpson G. M.: Teratogenicity of psychotherapeutic medications. Psychopharmacol Bull 23:531–585, 1987.PubMedGoogle Scholar
  69. 69.
    van Gent E. M., Nabarro G.: Haloperidol as an alternative to lithium in pregnant women (letter). Am J Psychiatry 144:1241, 1987.PubMedGoogle Scholar
  70. 70.
    Post R. M., Uhde T. W., Ballenger J. C., et al: Prophylactic efficacy of carbamazapine in manic— depressive illness. Am J Psychiatry 140:1602–1604, 1983.PubMedGoogle Scholar
  71. 71.
    Prien R. F., Gelenberg A. J.: Alternatives to lithium for preventive treatment of bipolar disorder, Am J Psychiatry 146:840–848, 1989.PubMedGoogle Scholar
  72. 72.
    Nidely J. R., Blake D. A., Freeman J. M., et al: Carbamazapine levels in pregnancy and lactation. Obstet Gynecol 53:139–140, 1979.Google Scholar
  73. 73.
    Nakne Y., Okuma T., Takahashi R., et al: Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: A report of a collaborative study group in Japan. Epilepsia 21:663–680, 1980.CrossRefGoogle Scholar
  74. 74.
    Paulson G. W., Paulson R. B.: Teratogenic effects of anticonvulsants. Arch Neurol 40:140–143, 1981.CrossRefGoogle Scholar
  75. 75.
    Sullivan F. M., McElhatton P. R.: A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and pyrimidone in mice. Toxicol Appl Pharmacol 40:365–378, 1977.PubMedCrossRefGoogle Scholar
  76. 76.
    Jones K. L., Lacro R. V., Johnson K. A., et al: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320:1661–1666, 1989.PubMedCrossRefGoogle Scholar
  77. 77.
    Dallesio D. J.: Seizure disorders in pregnancy. N Engl J Med 312:559–564, 1985.CrossRefGoogle Scholar
  78. 78.
    Cohen L. S., Heller V. L.: Manic depressive illness in pregnancy and the peurperium (letter). Psychosomatics, 1990, in press.Google Scholar
  79. 79.
    McElroy S. L., Keck P. E., Pope H. G., et al: Valproate in the treatment of rapid cycling mood disorder. J Clin Psychopharmacol 8:275–279, 1988.PubMedCrossRefGoogle Scholar
  80. 80.
    Lindhout D., Schmidt D.: In utero exposure to valproate and neural defects. Lancet 1:329–393, 1986.Google Scholar
  81. 81.
    Schou M.: What happened later to the lithium babies: A follow-up study of children born without malformations. Acta Psychiatr Scand 54:193–197, 1976.PubMedCrossRefGoogle Scholar
  82. 82.
    Cohen L. S., Rosenbaum J. F., Heller V. L.: Prescribing lithium for pregnant women (letter). Am J Psychiatry 145(6):773, 1988.Google Scholar
  83. 83.
    Weinstein M. R., Goldfield M. D.: Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 132:529–531, 1975.PubMedGoogle Scholar
  84. 84.
    Impasato D. J., Gabriel A. R., Lardara M.: Electric and insulin shock therapy during pregnancy. Dis Nerv Syst 25:542–546, 1964.Google Scholar
  85. 85.
    Wise M. G., Ward S. C., Townsend-Parchman W., et al: Case report of ECT during high-risk pregnancy. Am J Psychiatry 141:99–101, 1984.PubMedGoogle Scholar
  86. 86.
    Repke J. T., Berger N. G.: Electroconvulsive therapy in pregnancy. Obstet Gynecol 63(suppl):39–40, 1984.Google Scholar
  87. 87.
    Remick R. A., Maurice W. L.: ECT in pregnancy (letter). Am J Psychiatry 135:761–762, 1978.PubMedGoogle Scholar
  88. 88.
    Boyd J. H., Weissman M. M.: Epidemiology, in Paykel E. S. (ed): Handbook of Affective Disorders. New York, Guilford Press, 1982, p 6.Google Scholar
  89. 89.
    Istvon J.: Stress, anxiety, and birth outcome: A critical review of the evidence. Psychol Bull 100:331–348, 1986.CrossRefGoogle Scholar
  90. 90.
    Rementaria J. L., Blatt K.: Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J Pediatr 90:123–126, 1977.CrossRefGoogle Scholar
  91. 91.
    George D. T., Ladenheim J. A., Nutt D. J.: Effect of pregnancy on panic attacks. Am J Psychiatry 144:1078–1079, 1987.PubMedGoogle Scholar
  92. 92.
    Cohen L. S., Rosenbaum J. F., Heller V. L., et al: Course of panic disorder in 24 pregnant women. Presented at the 142nd annual meeting of the American Psychiatric Association, San Francisco, May 11, 1989.Google Scholar
  93. 93.
    Rosenbaum J. F.: The drug treatment of anxiety. N Engl J Med 306:401–404, 1982.PubMedCrossRefGoogle Scholar
  94. 94.
    Klein D. F.: Anxiety reconceptualized, in Klein D. F., Raskin J. (eds): Anxiety: New Research and Changing Concepts. New York: Raven Press, 1981.Google Scholar
  95. 95.
    Safra M. J., Oakley G. P.: Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet 2:478–480, 1975.PubMedCrossRefGoogle Scholar
  96. 96.
    Saxen I.: Association between oral clefts and drugs taken during pregnancy. Int J Epidemiol 4:37–44, 1975.PubMedCrossRefGoogle Scholar
  97. 97.
    Laegreid L., Olegard R., Wahlstrom J., et al: Abnormalities in children exposed to benzodiazepines in utero. Lancet 1:108–109, 1987.PubMedCrossRefGoogle Scholar
  98. 98.
    Winter R. M., Czeizel A., Lendvay A., et al: In-utero exposure to benzodiazepines. Lancet 1:627, 1987.CrossRefGoogle Scholar
  99. 99.
    Ballenger J. C.: Pharmacotherapy of panic disorders. J Clin Psychiatry 47(suppl 6):27–32, 1986.PubMedGoogle Scholar
  100. 100.
    Cohen L. S., Rosenbaum J. F.: Clonazepam: New uses and potential problems. J Clin Psychiatry 48(suppl):50–55, 1987.PubMedGoogle Scholar
  101. 101.
    Barry W. S., St. Clair S. M.: Exposure to benzodiazepines in utero (letter). Lancet 1:1436–1437, 1987.Google Scholar
  102. 102.
    Spier A. S., Tesar G. E., Rosenbaum J. F., et al: Clonazepam in the treatment of panic disorder and agoraphobia. J Clin Psychiatry 47:238–242, 1986.PubMedGoogle Scholar
  103. 103.
    Pollack M. H., Tesar G. E., Rosenbaum J. F., et al: Clonazepam in the treatment of panic disorder and agoraphobia: A one year follow-up. J Clin Psychopharmacol 6:302–304, 1986.PubMedCrossRefGoogle Scholar
  104. 104.
    Tesar G. E., Rosenbaum J. F., Pollack M. H., Sachs G. S., Herman J. B., Cohen L. S., Sidari J: Panic Disorder: Clonazepam versus alprazolam and placebo. New Research Section, American Psychiatric Association, 141 st Annual Meeting, Montreal, May 12, 1988.Google Scholar
  105. 105.
    Herman J. B., Rosenbaum J. F., Brotman, A. W.: The alprazolam to clonazepam switch for treatment of panic disorder. J Clin Psychopharmacol 7:175–178, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Lee S. Cohen
    • 1
    • 2
  • Jerrold F. Rosenbaum
    • 3
    • 2
  • Vicki L. Heller
    • 4
    • 5
  1. 1.Pregnancy Consultation Service, Clinical Psychopharmacology UnitMassachusetts General HospitalBostonUSA
  2. 2.Department of PsychiatryHarvard Medical SchoolBostonUSA
  3. 3.Clinical Psychopharmacology UnitMassachusetts General HospitalBostonUSA
  4. 4.Department of Obstetrics and GynecologyBeth Israel HospitalBostonUSA
  5. 5.Department of Obstetrics and GynecologyHarvard Medical SchoolBostonUSA

Personalised recommendations